AUTHORS
Andrew J. Portuguese, MD, Timothy Inocencio2, Peter Quon3, James Harnett, MS4, Zheng-Yi Zhou, PhD5, Nisha C Hazra, PhD, MS6, Michael K. Xu7, Jack Eales8, Hekun Chen9, Michelle Little, PhD10, Qiufei Ma, PhD11
AFFILIATIONS
1 Fred Hutchinson Cancer Center, Seattle, Washington, United States
2 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
3 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
4 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
5 Analysis Group, Inc., Boston, Massachusetts, United States
6 Analysis Group, Inc., Boston, Massachusetts, United States
7 Analysis Group, Inc., Boston, Massachusetts, United States
8 Analysis Group, Inc., Boston, Massachusetts, United States
9 Analysis Group, Inc., Boston, Massachusetts, United States
10 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
11 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
ABSTRACT
Introduction
Linvoseltamab and teclistamab are B-cell maturation antigen × CD3 bispecific antibodies approved in the US for adults with relapsed/refractory multiple myeloma (RRMM) who have received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody (i.e., triple-class exposed [TCE]). A prior cost-per-responder analysis (Portuguese AJ, et al. Curr Med Res Opin 2026), informed by an earlier matching-adjusted indirect comparison (MAIC; Lee HC, et al. Clin Lymph Myeloma Leuk 2025), suggested lower costs per clinical outcome for linvoseltamab versus teclistamab and elranatamab, driven by response and survival outcomes. An updated MAIC of linvoseltamab versus teclistamab (Lee HC, et al. ASCO 2026), using longer follow-up data from the LINKER-MM1 and MajesTEC-1 trials (median follow-up: 21.3 and 30.4 months, respectively), provides more mature comparative estimates for key clinical outcomes. This analysis updated the prior economic model using longer follow-up comparative efficacy estimates to estimate costs and cost per clinical outcome for linvoseltamab versus teclistamab.
Methods
A previously developed economic model was updated to estimate total cost per patient and per outcome over 1- and 2-year time horizons from a US commercial payer perspective. Costs included drug acquisition, administration, monitoring, adverse event (AE) management, progression related care, and terminal care. Treatment administration and dosing schedules followed US Prescribing Information (USPI); patients were assumed to switch to less frequent dosing at the earliest eligible time point. Efficacy data, duration of treatment (DOT), and AE incidence rates were drawn from pivotal trials (LINKER-MM1 and MajesTEC‑1); linvoseltamab efficacy and DOT were adjusted using updated MAIC data. MAIC adjusted estimates accounted for cross-trial differences in baseline characteristics available across LINKER-MM1 and MajesTEC-1. MAIC adjusted 2-year overall response rate, complete response or better (≥CR) rate, and very good partial response or better (≥VGPR) rate for linvoseltamab were 72%, 51%, and 63%, respectively; reported teclistamab rates were 63%, 46%, and 59%. Two-year progression-free (PF) months and life months were 16.9 and 18.5 for linvoseltamab, respectively, and 12.9 and 16.3 for teclistamab. Cost inputs were obtained from public sources (e.g., RED BOOK®, Centers for Medicare and Medicaid Services) and reported in 2026 US dollars. Key outcomes included total cost, cost per PF month, cost per life month, cost per responder, and pre-progression cost per month on treatment.
Results
Total estimated costs were 23.4% lower for linvoseltamab than for teclistamab at 1 year ($388,017 vs $506,266) and 25.8% lower at 2 years ($482,348 vs $650,225). Cost savings were driven primarily by lower drug acquisition costs, with additional savings for AE management, progression-related care, and drug administration, including hospitalization/monitoring associated with step-up dosing per USPI. Linvoseltamab demonstrated lower cost per outcome across all endpoints, reflecting both lower total costs and higher estimated survival and response outcomes. At 2 years, linvoseltamab had a lower cost per overall response reached ($669,927 vs $1,032,103), per patient reaching ≥CR ($945,779 vs $1,413,532), and per patient reaching ≥VGPR ($765,631 vs $1,102,076). Compared with teclistamab, linvoseltamab also had lower 2-year total cost per PF month ($28,575 vs $50,562) and per life month ($26,031 vs $39,989), as well as pre-progression cost per month on treatment ($31,627 vs $52,358). Lower cost per outcome findings with linvoseltamab were also observed over 1 year. In a scenario analysis assuming treatment to progression, 2-year total costs increased by 14% for linvoseltamab and 13% for teclistamab; however, linvoseltamab remained less costly overall ($548,440 vs $736,527).
Conclusions
In this updated model-based analysis incorporating longer follow-up comparative efficacy estimates and 2026 cost inputs, linvoseltamab was associated with lower estimated total costs and cost per clinical outcome than teclistamab over 1- and 2-year horizons. These findings were consistent with prior analyses and suggest that, under the model assumptions, linvoseltamab may provide a lower cost treatment option per response, PF month, and life month in patients with heavily pretreated TCE RRMM.
DISCLOSURES
Andrew J. Portuguese, MD: Regeneron Pharmaceuticals, Inc. - Research Funding; Pfizer, Inc. - Research Funding; Karyopharm Therapeutics Inc. - Consultancy (Includes expert testimony)